Viking Therapeutics has multiple promising drugs in its portfolio that could generate billions in future revenue. Approval of VK2735 and VK2809 could lead to a surge in the stock's value.

Claim your 7-day free trial now. Vera Therapeutics, Inc. VERA said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Maze Therapeutics, Inc. before investing. In this article, we go over a few key ...

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases.

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases.

LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual ...

March 31, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq ... with participation from Janus Henderson Investors and Logos Capital. Approximately $40 million of the $115 million represented ...

Caledonia Mining Corp PLC (CMCL), Celcuity Inc (CELC), i-80 Gold Corp (IAU), LanzaTech Global Inc (LNZA), Loar Holdings Inc (LOAR), Maze Therapeutics Inc (MAZE), Nano-X Imaging Ltd (NNOX), Omeros ...

March 31, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq ... with participation from Janus Henderson Investors and Logos Capital. Approximately $40 million of the $115 million ...

March 31, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (MAZE), a clinical ... with participation from Janus Henderson Investors and Logos Capital. Approximately $40 million of the $115 million ...